Page 363

_ 363 Item Details($) Appropriations($) ITEM 275. First Year Second Year First Year Second Year FY2025 FY2026 FY2025 FY2026 opioid overdose reversal agent and improve access, quality, and availability through a domestic supply. Funding provided to the contracting entity may be used for: (i) investment in research and development activities supporting an opioid overdose reversal agent API, formulation development, manufacturing process qualification and validation, and regulatory approval; and (ii) capital expenditures, including custom machinery for assembly of the drug/device combination product and semi-automated packaging. All intellectual property developed by the program would be owned by the private entity and all capital expenditures, including custom equipment, would be owned by the Authority or partner agency. 276. Health Research, Planning, and Coordination (40600) $24,441,725 $24,331,725 $25,030,406 Health Research, Planning and Coordination (40603) $4,833,106 $4,723,106 Regulation of Health Care Facilities (40607) $16,912,088 $16,912,088 $17,610,769 Certificate of Public Need (40608) $1,805,325 $1,805,325 Cooperative Agreement Supervision (40609) $891,206 $891,206 Fund Sources: General $6,387,762 $6,277,762 $7,450,743 Special $3,593,948 $3,593,948 Dedicated Special Revenue $627,006 $627,006 Federal Trust $13,833,009 $13,833,009 $13,358,709 Authority: §§ 32.1-102.1 through 32.1-102.11; 32.1-122.01 through 32.1-122.08; and 32.1-123 through 32.1-138.5, Code of Virginia; and P.L. 96-79, as amended, Federal Code; and Title XVIII and Title XIX of the U.S. Social Security Act, Federal Code. A.1. Supplemental funding for the regional health planning agencies shall be provided from the following sources: 2. Special funds from Certificate of Public Need (40608) application fees in excess of those required to operate the COPN Program, provided the program may retain special fund balances each year equal to three months operational needs in case of revenue shortfalls in the subsequent year. 3. The Department of Health shall revise annual agreements with the regional health planning agencies to require an annual independent financial audit to examine the use of state funds and the reasonableness of those expenditures. B. Failure of any regional health planning agency to establish or sustain business operations shall cause funds to revert to the Central Office to support health planning and Certificate of Public Need functions. C. Out of this appropriation, $690,000 the first year and $690,000 the second year from the general fund shall be provided to the Virginia Office of Rural Health, as the state match for the federal Office of Rural Health Policy Grant. D. Out of this appropriation, $278,000 the first year and $278,000 the second year shall be provided to the department from statewide indirect cost recoveries to match federal funds and support the programs of the Office of Licensure and Certification. Amounts recovered in excess of the special fund appropriation shall be deposited to the general fund. E. The Virginia Department of Health (VDH) in collaboration with the Department of Health Professions shall issue risk mitigation guidelines on the prescription of the class of potent pain medicines known as extended-release and long-acting (ER/LA) opioid analgesics to include co-prescription of an opioid antagonist, approved by the U.S. Food and Drug Administration (FDA), for administration by family members or caregivers in a non-medically supervised environment. F. The Virginia Department of Health shall provide administrative and technical support to the Virginia Partners in Prayer Program through its Office of Health Equity. The cost of